Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Thursday, March 28, 2024
China Medical System (867.HK) 2023 Annual Results: Despite of the Temporary Financial Performance Pressure, Fresh Catalysts Emerged from Successive Innovation Breakthroughs
Sunday, February 4, 2024
China Medical System (00867) Obtained Exclusive License of a First-line Phosphate-lowering Drug Velphoro(R)
Tuesday, January 2, 2024
CMS(00867) Joins Hands with Pharmaron to Promote the Singapore Manufacturing Plant Acquisition and CDMO Business in SEA
Wednesday, December 13, 2023
China Medical System: 4 Products Have Been Newly Included or Continued to be Included in the NRDL
Monday, December 4, 2023
China Medical System: NDA for Additional RA Indication of Methotrexate Injection Accepted in China
Thursday, August 24, 2023
China Medical System Gained Exclusive License of an Anti-Ischemic Stroke Class 1 Innovative Drug
Monday, July 31, 2023
China Medical System Once Again Received MSCI-ESG 'AA' Rating, Leading the Industry in ESG Management
Thursday, June 29, 2023
China Medical System Included in the First 'Sustainability Yearbook (China)' of S&P Global
Monday, June 12, 2023
China Medical System: The first 'Diazepam Nasal Spray' Approved for Marketing in China
Tuesday, May 30, 2023
China Medical System: An Innovative Drug, ILUMETRI 'Tildrakizumab Injection' Approved for Marketing in China

Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: